浙江力諾(300838.SZ):擬以2.6億元購買徐化機100%股權
格隆匯6月6日丨浙江力諾(300838.SZ)公佈,公司第五屆董事會第八次會議、第五屆監事會第八次會議審議通過《關於擬收購徐州化工機械有限公司100%股權的議案》,同意公司與程路、李姝、耿世紀等20人/社團法人以及徐州化工機械有限公司(以下簡稱“徐化機”或“標的公司”)簽署《浙江力諾流體控制科技股份有限公司與程路、李姝、耿世紀等20人/社團法人關於徐州化工機械有限公司收購協議》,擬以現金2.6億元購買標的公司原股東持有的股權的方式取得徐化機100%股權,待本次股權轉讓完成後,徐化機將成爲浙江力諾的全資子公司,將納入公司合併報表範圍內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.